Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.
Status:
Recruiting
Trial end date:
2024-12-20
Target enrollment:
Participant gender:
Summary
To evaluate the safety of Fosaprepitant Dimeglumine Injection for the prevention of nausea
and vomiting caused by tumor chemotherapy drugs, analyze the characteristics of the
applicable population and clinical medication of Fosaprepitant Dimeglumine, evaluate the risk
factors that may affect the efficacy of drug use, and compare the clinical benefits of
different drug use modes.